Paul Tudor Jones’s Apogee Therapeutics APGE Stock Holding History

Paul Tudor Jones’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.74M	Buy	+35,734	New	+$3.22M	0.01%	1320
2026 Q1	–	Sell	-30,039	Closed	-$2.27M	–	3566
2025 Q4	$2.27M	Buy	+30,039	New	+$1.89M	﹤0.01%	1724
2024 Q2	–	Sell	-12,522	Closed	-$832K	–	2293
2024 Q1	$832K	Buy	+12,522	New	+$547K	0.01%	1420
2023 Q4	–	Sell	-12,515	Closed	-$267K	–	2340
2023 Q3	$267K	Buy	+12,515	New	+$276K	﹤0.01%	1971

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Paul Tudor Jones's APGE Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 35,734 shares worth $4.74M. The stake represents 0.01% of the portfolio and ranks #1320 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in APGE as recently as Q4 2025.

Paul Tudor Jones first reported a position in APGE in Q3 2023 and has held it in 4 quarters since. 285 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Paul Tudor Jones held 35,734 shares of Apogee Therapeutics worth $4.74M as of Q2 2026.
Apogee Therapeutics was a new Paul Tudor Jones position in Q2 2026.
Apogee Therapeutics made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1320 holding.
Paul Tudor Jones first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 4 quarters since.
285 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.